Efficacy of dendritic cells matured early with OK-432 (Picibanil), prostaglandin E2, and interferon-alpha as a vaccine for a hormone refractory prostate cancer cell line.
Dendritic cells (DCs) are potent antigen-presenting cells. OK432 (Picibanil) was introduced as a potent stimulator of DC maturation in combination with prostaglandin-E(2) and interferon-alpha. We compared the efficacy of a DC-prostate cancer vaccine using early-mature DCs stimulated with OK432, PGE2 and INF-alpha (OPA) with that of vaccines using other methods. On days 3 or 7 of DC culture, TNF-alpha (T), TNF-alpha and LPS (TL) or OPA were employed as maturation stimulators. DU145 cells subjected to heat stress were hybridized with mature DCs using polyethyleneglycol. T cells were sensitized by the hybrids, and their proliferative and cytokine secretion activities and cytotoxicity were measured. The yields of early-mature DCs were higher, compared to yields at the conventional maturation time (P<0.05). In the early maturation setting, the mean fusion ratios, calculated from the fraction of dual-positive cells, were 13.3%, 18.6%, and 39.9%, respectively (P=0.051) in the T only, TL, and OPA-treated groups. The function of cytotoxic T cells, which were sensitized with the hybrids containing DCs matured early with OPA, was superior to that using other methods. The antitumor effects of DC-DU145 hybrids generated with DCs subjected to early maturation with the OPA may be superior to that of the hybrids using conventional maturation methods.
Yoo
Changhee
C
Department of Urology, College of Medicine, Hallym University, Hallym Sacred Heart Hospital, Anyang, Korea.
Do
Hyun-Ah
HA
Jeong
In Gab
IG
Park
Hongzoo
H
Hwang
Jung-Jin
JJ
Hong
Jun Hyuk
JH
Cho
Jin Seon
JS
Choo
Myong-Soo
MS
Ahn
Hanjong
H
Kim
Choung-Soo
CS
D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D015232:Dinoprostone / Q000494:pharmacology*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D016898:Interferon-alpha / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000276:immunology*; D010641:Phenotype; D010844:Picibanil / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D019496:Cancer Vaccines; D007155:Immunologic Factors; D016898:Interferon-alpha; D008070:Lipopolysaccharides; D010844:Picibanil; D015232:Dinoprostone
Immunol Lett. 2005 Nov 15;101(2):154-9
15993950
J Immunol. 1997 Mar 15;158(6):2919-25
9058830
Anticancer Res. 2002 Jul-Aug;22(4):2137-45
12174895
Eur J Immunol. 1997 Nov;27(11):3031-8
9394834
J Immunol. 2007 Jan 1;178(1):613-22
17182602
Biomed Pharmacother. 2006 May;60(4):156-60
16647239
J Exp Med. 1997 Oct 20;186(8):1183-7
9379142
J Immunother. 2007 May-Jun;30(4):359-69
17457211
Acta Odontol Scand. 2001 Jun;59(3):124-30
11501880
Int J Oncol. 2006 Nov;29(5):1263-8
17016660
Int J Cancer. 2004 May 1;109(5):685-90
14999775
Vox Sang. 2003 Apr;84(3):228-36
12670372
J Immunol. 1998 Sep 15;161(6):3042-9
9743369
Cancer Immunol Immunother. 2003 Apr;52(4):207-14
12669245
J Immunother. 2006 Jan-Feb;29(1):67-77
16365602
J Exp Med. 1994 Oct 1;180(4):1263-72
7523569
Med Oncol. 2004;21(2):155-65
15299188
J Immunol. 2007 Oct 1;179(7):4874-83
17878387
Apoptosis. 2006 Sep;11(9):1513-24
16738802
J Immunother. 2004 Jul-Aug;27(4):265-72
15235387